CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.
Saved in:
| Title: | CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia. |
|---|---|
| Authors: | Valtis YK; Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Lin C; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC., Nemirovsky D; Biostatistics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Devlin S; Biostatistics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Rejeski K; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Curran KJ; Cell Therapy and Cell Engineering Facility, Center for Cell Engineering, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY., Wang X; Cell Therapy and Cell Engineering Facility, Center for Cell Engineering, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY., Shah NN; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Jeyakumar N; Division of Hematology/Oncology, Stanford University School of Medicine, Palo Alto, CA., Miller K; Quantitative Sciences Unit, Biomedical Informatics Research (BMIR) Division, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA., Zhang A; Quantitative Sciences Unit, Biomedical Informatics Research (BMIR) Division, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA., Kota VK; Division of Hematology and Medical Oncology, Georgia Cancer Center at Augusta University, Augusta, GA., Al Darobi AH; Section of Hematology, Department of Medicine, Banner MD Anderson Cancer Center, Gilbert, AZ., Muhsen I; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX., Sasine J; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA., Aldoss I; Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA., Advani AS; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Reshef R; Blood and Marrow Transplantation and Cell Therapy Program, Department of Medicine, Columbia University Irving Medical Center, New York, NY., Chen EC; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Kopmar N; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington School of Medicine, Seattle, WA., Tsai SB; Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL., Hilal T; Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ., Shah BD; Moffitt Cancer Center and Research Institute, Tampa, FL., Faramand R; Moffitt Cancer Center and Research Institute, Tampa, FL., Solh MM; Northside Hospital Cancer Institute, Atlanta, GA., Tan V; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR., Bezerra E; Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, OH., Battiwalla M; Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, Division of Hematology and Oncology, Department of Internal Medicine, HCA Healthcare, Nashville, TN., Ramakrishnan A; Sarah Cannon Transplant and Cellular Therapy Program at St. David's South Austin Medical Center, Division of Hematology/Oncology, Department of Internal Medicine, HCA Healthcare, Austin, TX., Mathews J; Sarah Cannon Transplant and Cellular Therapy Program at Texas Oncology, Division of Hematology and Oncology, Department of Internal Medicine, HCA Healthcare, Dallas, TX., Shaughnessy P; Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, Division of Hematology and Oncology, Department of Internal Medicine, HCA Healthcare, San Antonio, TX., Mountjoy L; Sarah Cannon Transplant and Cellular Therapy Program at Colorado Blood Cancer Institute, Division of Hematology and Oncology, Department of Internal Medicine, HCA Healthcare, Denver, CO., Hoeg RT; Division of Cellular Therapy, Bone Marrow Transplantation and Malignant Hematology, Department of Internal Medicine, University of California Davis, Sacramento, CA., Dykes KC; Division of Hematology and Medical Oncology, University of California San Diego, La Jolla, CA., Logan AC; Division of Hematology and Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Kumaran MV; Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology and Oncology, Department of Medicine, University of Arkansas Medical Center, Little Rock, AR., Schwartz M; Division of Hematology, Department of Medicine, University of Colorado, Aurora, CO., Tracy S; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Moore J; Division of Hematology and Oncology, Department of Internal Medicine, Wilmot Cancer Institute of University of Rochester, Rochester, NY., Odstrcil Bobillo S; Division of Hematology and Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Frey NV; Division of Hematology and Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA., Connor M; Division of Hematology and Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA., Ladha A; Department of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA., Dholaria B; Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN., Sutherland K; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA., Roloff GW; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL., Muffly LS; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA., Park JH; Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. |
| Source: | Blood advances [Blood Adv] 2026 Jan 13; Vol. 10 (1), pp. 276-288. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
